Feature|Articles|April 17, 2024
- Pharmaceutical Executive: April 2024
- Volume 44
- Issue 4
Pharmaceutical Executive: April 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 2 years ago
Power in Partneringabout 2 years ago
The IRA Impact: Navigating Its Evolving Complexitiesabout 2 years ago
Fighting for Innovationabout 2 years ago
Say Hello to Flexible: Reimagining the Patient Journeyabout 2 years ago
Aspiring for the C-Suite? Consider Being a Chief of Staffabout 2 years ago
Latent Benefit of Access Restrictions for Rare Conditionsabout 2 years ago
The Biotech Rally has Legs—But Rising Tide Isn’t Lifting All Boatsabout 2 years ago
The Pharmaceutical Playbook for Asia’s Private Marketabout 2 years ago
Operating Models for Successful DOL EngagementAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
3
The Risks and Benefits of FDA Reviewing Real-Time Data
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5